The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC.
Joanne B WeidhaasChen HuRitsuko KomakiGregory A MastersGeorge R BlumenscheinJoe Y ChangBo LuAdam P DickerJeffrey A BogartYolanda I GarcesSamir NarayanClifford G RobinsonVivek S KavadiJoel S GreenbergerChristopher D KoprowskiJames W WelshElizabeth M GoreRobert M MacRaeRebecca PaulusJeffrey BradleyPublished in: Cancer research communications (2023)
Although an overall survival advantage was not achieved in KRAS-variant patients, there is potential impact of cetuximab for this genetic subset of patients. In contrast, cetuximab seems to harm non-variant patients. These findings further support the importance of genetic patient selection in trials studying the addition of systemic agents to radiotherapy.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- small cell lung cancer
- early stage
- gene expression
- patient reported outcomes
- squamous cell carcinoma
- computed tomography
- risk assessment
- case report
- copy number
- tyrosine kinase
- human health
- metastatic colorectal cancer
- free survival
- radiation induced